Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
09 Setembro 2023 - 9:00PM
Business Wire
IDgenetix is a clinically validated
pharmacogenomic (PGx) test that incorporates the results of
drug-gene interactions with drug-drug interactions and lifestyle
factors, such as smoking and use of over-the-counter medicines and
dietary supplements, to provide medication recommendations for
patients with mental health conditions
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced data from a study showing the addition of drug-drug
interactions and lifestyle factors to drug-gene interactions
provided by its IDgenetix® test significantly impacted the number
of drug recommendations and contributed to improved remission rates
for patients with moderate to severe depression. The data was
shared at Psych Congress 2023 in a poster titled, “The Importance
of Incorporating Drug-Drug Interactions and Lifestyle Factors in
Pharmacogenomics-Guided Medication Management for Patients with
Major Depressive Disorder in a Randomized Controlled Trial.”
“There are many factors that can impact how a patient responds
to and metabolizes mental health medication, such as their
genetics, other drugs being taken and lifestyle choices like
smoking,” said Robert Cook, Ph.D., senior vice president of
research and development at Castle Biosciences. “This study
reinforces the value of our IDgenetix test in providing
personalized information for each patient, taking drug-gene,
drug-drug and lifestyle factor interactions into account, to guide
optimal medication selection that may help patients with depression
achieve faster remission from their symptoms.”
IDgenetix is supported by a published randomized controlled
trial (RCT) showing that patients whose medication management was
guided by the test were 2.65 times more likely to achieve remission
of depressive symptoms compared to patients whose medication
management was guided by the standard-of-care, trial-and-error
approach.1 The study shared at Psych Congress 2023 evaluated the
contribution of drug-gene, drug-drug and lifestyle factors to
IDgenetix-guided medication management in patients with moderate to
severe depression from this RCT (n=261).
The non-genetic information (drug-drug interactions and
lifestyle factors) accounted for 43% of all drug recommendations in
study participants, while single-gene testing for CYP2D6 and
CYP2C19 contributed to only 22%. At 12 weeks, patients whose
medication management was guided by IDgenetix had a remission rate
of 41%, compared to only 27% of patients whose medication
management was not guided by the test (p=0.03, risk ratio=1.49
[1.05-2.12]). Among a subset of the patients taking actionable
antidepressants at baseline (n=106), remission rates were even more
significantly improved for the IDgenetix-guided group compared to
the unguided group (47% vs. 22%, p=0.01, risk ratio=2.15
[1.16-3.96]).
The poster can be viewed here and will also be published on HMP
Global’s Psychiatry & Behavioral Health Learning Network in
approximately 30-60 days.
About IDgenetix®
IDgenetix® is an advanced pharmacogenomic (PGx) test designed to
guide medication selection and management for patients with
neuropsychiatric conditions, such as depression and anxiety.
IDgenetix provides important genetic information to clinicians to
help guide personalized treatment plans for their patients, with a
goal of helping patients achieve faster therapeutic response and
improving their chances of remission by identifying appropriate
medications more efficiently than the standard-of-care,
trial-and-error approach. IDgenetix integrates drug-gene, drug-drug
and lifestyle factor interactions in a clinically actionable report
and is supported by a published, peer-reviewed randomized
controlled trial that demonstrated clinical utility over the
standard of care when physicians reviewed IDgenetix results prior
to prescribing a medication. More information can be found at
www.IDgenetix.com.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: the potential of IDgenetix to
provide personalized information for each patient to guide optimal
medication selection that may help patients with depression achieve
faster remission from their symptoms. The words “can,” “may,”
“potential,” “will” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. We may
not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that we make. These forward-looking statements involve
risks and uncertainties that could cause our actual results to
differ materially from those in the forward-looking statements,
including, without limitation: subsequent study or trial results
and findings may contradict earlier study or trial results and
findings or may not support the results shown in this study,
including with respect to the discussion of IDgenetix in this press
release; actual application of our tests may not provide the
aforementioned benefits to patients; and the risks set forth under
the heading “Risk Factors” in our Annual Report on Form 10-K for
the year ended December 31, 2022 and in our other filings with the
SEC. The forward-looking statements are applicable only as of the
date on which they are made, and we do not assume any obligation to
update any forward-looking statements, except as may be required by
law.
1. Bradley P, Shiekh M, Mehra V, et al. Improved efficacy with
targeted pharmacogenetic-guided treatment of patients with
depression and anxiety: A randomized clinical trial demonstrating
clinical utility. J Psychiatr Res. 2018 Jan;96:100-107. doi:
10.1016/j.jpsychires.2017.09.024. Epub 2017 Sep 23. PMID:
28992526.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230909285042/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024